Workshop Day
Wednesday, November 20

WORKSHOP A

Exploring Shared/Public Neoantigens to Increase the Commercial Success of Neoantigen-based Therapies
09:00 - 12:00

Patient specific neoantigen therapies pose significant practical and regulatory challenges. However, targeting shared neoantigens across patients can mean highly effective off-the-shelf cancer vaccines. Join this workshop discussion to identify where the challenges lie in targeting shared neoantigens for off-the-shelf immunotherapy.

Attendees will learn and discuss:

• Identification of shared neoantigens – approaches and data to date
• How to use shared neoantigens therapeutically
• Early clinical data – what are we learning?

Workshop Leader

Andrew Allen - Gritstone

Andrew Allen
CEO
Gritstone Therapeutics

Andrew Allen is co-founder of Gritstone Oncology, and President, CEO and a member of the BoD since August 2015. Previously he co-founded and was CMO at Clovis Oncology (NASDAQ: CLVS), and prior to that was CMO at Pharmion (acquired by Celgene in 2008 for $2.9B). He trained in Medicine at Oxford University, obtained a PhD in Immunology at Imperial College, and worked for several years at McKinsey & Company. He serves on the BoD of Epizyme (NASDAQ:EPZM), Sierra Oncology (NASDAQ:SRRA) and Revitope (private). He served on the BoD of Cell Design Labs, Inc until acquisition by Gilead in Dec 2017.

WORKSHOP B

Mechanisms of Immunotherapy Response and Resistance in Pancreatic Cancer
13:00 - 16:00

Pancreatic cancer is a lethal malignancy that evades many current treatments, including immunotherapy. Understanding the obstacles that this cancer poses to the immune system can be revealed by faithful mouse models in which tumor-antigen specific T cells can be interrogated longitudinally. We have identified combination immunotherapies that show preclinical promise by altering the qualities of tumor-specific T cells. Underlying mechanisms mediating therapeutic activity are actively under investigation and will be discussed in detail.

Attendees will learn and discuss:

• How immunotherapies can be combined for safely and effectively targeting pancreatic cancer in preclinical studies

• Understanding how combinations mechanistically interact to induce durable immunity through antigen presenting cells and tumor antigen-specific T cells in pancreatic cancer

• Identifying tumor escape mechanisms following combination immunotherapies to inform next generation strategies to anticipate and overcome resistance

Ingunn

Ingunn Stromnes
Assistant Professor
University of Minnesota

Department of Immunology at the University of Washington and completed her postdoctoral training at the Fred Hutchinson Cancer Research Center where she pioneered an adoptive T cell therapy for the particular lethal cancer, pancreatic ductal adenocarcinoma. She started her laboratory at the University of Minnesota in 2017 where her lab is developing model systems to interrogate mechanisms of immunotherapy response and resistance in pancreatic cancer. Her research is designed to understand how to develop immunotherapies, both by engineering lymphocytes and combination immunotherapies to create safe and durable immunotherapies for advanced cancer patients.